Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced positive preliminary data from an ongoing Phase 1/2 trial of its investi...
Principia Biopharma (NASDAQ: PRNB ) announces positive preliminary data from Part B of its open-label Phase 2 clinical trial evaluating lead candidate PRN1008 in pemphigus patients. More news on: Principia Biopharma Inc., Healthcare stocks news, Stocks on the move, Read more ...
Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Principia Bioph...
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced t...
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced t...
Principia Biopharma (NASDAQ: PRNB ): Q2 EPS of $0.28 may not be comparable to consensus of -$0.65. More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced fin...
SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced upd...
IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...
IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...